cyc 202 has been researched along with Bone Cancer in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gu, X; Liu, Y; Ma, Z; Zhang, J; Zhang, R; Zheng, Y | 1 |
| Al-Omran, M; de Nigris, F; Giordano, A; Infante, T; Mancini, FP; Minucci, PB; Napoli, C; Schiano, C; Zullo, A | 1 |
| Bach, S; Filipski, E; Gianella-Borradori, A; Iacobelli, S; Iurisci, I; Lévi, F; Meijer, L; Reinhardt, J | 1 |
3 other study(ies) available for cyc 202 and Bone Cancer
| Article | Year |
|---|---|
Intrathecal administration of roscovitine attenuates cancer pain and inhibits the expression of NMDA receptor 2B subunit mRNA.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Injections, Spinal; Male; Mice; Mice, Inbred C3H; Pain; Protein Subunits; Purines; Random Allocation; Receptors, N-Methyl-D-Aspartate; RNA, Messenger; Roscovitine; Xenograft Model Antitumor Assays | 2012 |
Osteosarcoma cells induce endothelial cell proliferation during neo-angiogenesis.
Topics: Animals; Antineoplastic Agents; Aorta; Apoptosis; Bone Neoplasms; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Cell Survival; Culture Media; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 5; Endothelial Cells; Female; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Osteosarcoma; Purines; Roscovitine; Up-Regulation; YY1 Transcription Factor | 2013 |
Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Cycle; Circadian Rhythm; Gene Expression; Male; Mice; Osteosarcoma; Protein Kinase Inhibitors; Purines; Roscovitine; Transcription, Genetic | 2006 |